

Response to: 'Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?' by Teng *et al*

The letter by Dr Teng and colleagues¹ describes an interesting intellectual exercise. In showing that the scores of the European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)^{2,3} correlate very well ($r=0.81$) with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) in their SLE patient cohort, they have added disease activity to the concepts inter-related to the new SLE criteria. These relationships, which were discussed for SLE disease severity or 'ominosity' early in the criteria development process,^{2,3} may have more overlap than we usually think based on theoretical concepts. In this way, the data by Dr Teng *et al*¹ add to the proof of face validity of the EULAR/ACR criteria.

While the tools to assess criteria versus disease activity may share certain domains and weight, there are relevant distinctions for capturing disease activity. In particular, sensitivity to change of individual domains and its relation to damage accrual appears to be crucial and requires different validation than classification.

However, the fact that the SLEDAI correlates with the EULAR/ACR criteria better than the revised systemic lupus activity measure ($r=0.61$) may also point to construct criteria the EULAR/ACR criteria share with the SLEDAI.⁴ Both have weighted items, even though the weights are based on different reasoning. Both count each individual item in a categorical way. Both have limited themselves to a feasible number of items. Moreover, while not so obvious an overlap, a useful SLE activity score should have significant specificity for SLE.

For the EULAR/ACR 2019 classification criteria, it is also obvious that most of the criteria items are indeed associated with activity. This is true for all clinical items, which are only present in active disease, but also for low complements and for antibodies to double-stranded DNA (dsDNA). The arguable exceptions are anti-Sm antibodies and antiphospholipid antibodies, but anti-Sm antibodies without concomitant anti-dsDNA antibodies are relatively uncommon, and antiphospholipid antibodies carry a low weight in the new criteria system.^{2,3} This makes the correlation understandably robust.

At the same time, and this is of importance, the SLEDAI is based on counting only currently active disease. In contrast, the classification criteria count items not only on a given day but also historically present.^{2,3,5} For classification, it is sufficient to have had this organ manifestation once.^{2,3,6,7} This is a major and important difference to the approach taken by Dr Teng and colleagues.¹ Their clever approach is revealing as an intellectual exercise, which we highly appreciate. However, it should not lead to the erroneous idea that this was a legitimate use of the EULAR/ACR classification criteria. Modifying important parameters, such as an item having been present to be sufficient for classification, would change outcomes.

Martin Aringer ,¹ Karen Costenbader,² Thomas Dörner ,³ Sindhu R Johnson ⁴

¹Division of Rheumatology, Department of Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
²Division of Rheumatology and Immunology, Department of Medicine, Brigham and Womens Hospital, Harvard Medical School, Boston, Massachusetts, USA
³Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
⁴Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

Correspondence to Professor Martin Aringer, Internal Medicine III, Medical Faculty, Technical University of Dresden, Dresden 01307, Germany; martin.aringer@uniklinikum-dresden.de

Contributors All four authors have drafted the response together and approved of the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, reporting or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not required.

Provenance and peer review Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Aringer M, Costenbader K, Dörner T, *et al.* *Ann Rheum Dis* 2022;**81**:e23.

Received 5 February 2020

Accepted 6 February 2020

Published Online First 2 March 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-217017>

Ann Rheum Dis 2022;**81**:e23. doi:10.1136/annrheumdis-2020-217105

ORCID iDs

Martin Aringer <http://orcid.org/0000-0003-4471-8375>

Thomas Dörner <http://orcid.org/0000-0002-6478-7725>

Sindhu R Johnson <http://orcid.org/0000-0003-0591-2976>

REFERENCES

- Teng J, Zhou Z, Wang F, *et al.* Do 2019 European League against Rheumatism/American College of rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity? *Ann Rheum Dis* 2022;**81**:e22.
- Aringer M, Costenbader K, Daikh D, *et al.* 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis* 2019;**78**:1151–9.
- Aringer M, Costenbader K, Daikh D, *et al.* 2019 European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Arthritis Rheumatol* 2019;**71**:1400–12.
- Bombardier C, Gladman DD, Urowitz MB, *et al.* Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on prognosis studies in SLE. *Arthritis Rheum* 1992;**35**:630–40.
- Tedeschi SK, Johnson SR, Boumpas D, *et al.* Developing and refining new candidate criteria for systemic lupus erythematosus classification: an international collaboration. *Arthritis Care Res* 2018;**70**:571–81.
- Tan EM, Cohen AS, Fries JF, *et al.* The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;**25**:1271–7.
- Petri M, Orbai A-M, Alarcón GS, *et al.* Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;**64**:2677–86.